Findings

What do systematic reviews say?

26 questions · 26 findings · 8 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 57.7%GRADE not reported 8 · 30.8%Very low 1 · 3.8%Low 1 · 3.8%Moderate 1 · 3.8%High 0 · 0%

Oral ciclosporin vs azathioprine (AZA)

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral methotrexate vs oral chloroquine

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral chloroquine vs placebo

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral methotrexate vs placebo

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral antibiotics vs placebo

Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis

1 finding from 1 review

Interventions to reduce Staphylococcus aureus in the management of eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Moderate

Oral hydroxychloroquine vs placebo

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

Health‐related quality of life (AQoL‐8D) · adults with alopecia areata

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Very low

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Complete cure and adverse events for terbinafine vs placebo

Quality of life · participants with confirmed toenail onychomycosis

The review found no eligible studies for this question.

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azoles vs placebo

Quality of life · participants with confirmed toenail onychomycosis

The review found no eligible studies for this question.

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Griseofulvin vs azole

Quality of life · participants with confirmed toenail onychomycosis

The review found no eligible studies for this question.

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Griseofulvin vs terbinafine

Quality of life · participants with confirmed toenail onychomycosis

The review found no eligible studies for this question.

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Combination terbinafine plus azole vs terbinafine

Quality of life · participants with confirmed toenail onychomycosis

The review found no eligible studies for this question.

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azoles vs terbinafine

Quality of life · participants with confirmed toenail onychomycosis

The review found no eligible studies for this question.

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobetasol propionate cream vs prednisone

Quality of life ‐ not measured · bullous pemphigoid

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FAE vs placebo

QoL · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 175 participants
Low

Fluticasone propionate spray vs Betamethasone sodium phosphate mouthwash

Secondary outcome: Dermatology Quality of Life measure · People with erosive oral lichen planus

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No statistical testing of the Oral Health Quality of Life index (OHQoL16) was reported in Hegarty 2002 (fluticasone mean score 0.7 versus betamethasone mean score -0.8).
1 study · 22 participants
GRADE not reported